Global Cardiovascular Drug Market Research and Forecast 2018-2023
Cardiovascular disease (CVD) involves heart and blood vessel blockage which leads to heart attack, chest pain and other heart problems. It is one of the leading cause of death worldwide. CVD mainly caused due to high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol consumption. Factors motivating the growth of CVD drug market includes increasing geriatric population and changing lifestyle such as shift in work hours. Advancement in cardiovascular diagnosis procedure and technological improvement in the healthcare have fuelled the growth of this market. Growing healthcare expenditure in emerging economies and cost-effective and affordable cardiovascular solution by leading manufacturers have provided new opportunity to this market.
Geographically, Cardiovascular drug market is divided into North America, Europe, Asia Pacific and Rest of the World. In terms of revenue generation North America region represents the largest market for cardiovascular drugs. Adoption of genetic engineering in U.S for diagnosis of cardiovascular diseases is another driving factor. Increasing government funding to improve healthcare infrastructure, and rising awareness about cardiovascular drug are the major factor which drives this market in APAC region.
The global players in the cardiovascular drug market include Abbott laboratories, Bristol-Myers Squibb company, Sanofi, Boston scientific, C.R bard. The strategy adopted in these companies are continuous investments in (R&D) which made them progress over the past several years in offering better drug with minimum side effects. As a result, market player may offer low-cost, high-value solutions and services to various community hospitals and clinics. In January 2018, Sanofi acquired Ablynx to expand their product portfolio for rare blood disorders and continue to advance the strategic transformation for drug discovery.
RESEARCH METHODOLOGY
The market study of Global Cardiovascular drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as the FDA, WHO and others
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
The Report is intended for cardiovascular drug manufacturers, cardiovascular drug API manufacturer, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating in delivering insights into the market for better business decisions.
THE REPORT COVERS:
Comprehensive research methodology of Global Cardiovascular drug market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Cardiovascular drug market.
Insights about market determinants which are stimulating the Global Cardiovascular drug market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Geographically, Cardiovascular drug market is divided into North America, Europe, Asia Pacific and Rest of the World. In terms of revenue generation North America region represents the largest market for cardiovascular drugs. Adoption of genetic engineering in U.S for diagnosis of cardiovascular diseases is another driving factor. Increasing government funding to improve healthcare infrastructure, and rising awareness about cardiovascular drug are the major factor which drives this market in APAC region.
The global players in the cardiovascular drug market include Abbott laboratories, Bristol-Myers Squibb company, Sanofi, Boston scientific, C.R bard. The strategy adopted in these companies are continuous investments in (R&D) which made them progress over the past several years in offering better drug with minimum side effects. As a result, market player may offer low-cost, high-value solutions and services to various community hospitals and clinics. In January 2018, Sanofi acquired Ablynx to expand their product portfolio for rare blood disorders and continue to advance the strategic transformation for drug discovery.
RESEARCH METHODOLOGY
The market study of Global Cardiovascular drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as the FDA, WHO and others
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
The Report is intended for cardiovascular drug manufacturers, cardiovascular drug API manufacturer, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating in delivering insights into the market for better business decisions.
THE REPORT COVERS:
Comprehensive research methodology of Global Cardiovascular drug market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Cardiovascular drug market.
Insights about market determinants which are stimulating the Global Cardiovascular drug market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING ENVIRONMENTAL POLLUTION, EXCESSIVE ALCOHOL CONSUMPTION & SMOKING.
3.1.2. CHANGING LIFESTYLE & SHIFTS IN WORK HOURS.
3.1.3. TECHNOLOGICAL ADVANCEMENT IN HEALTHCARE.
3.1.4. INCREASING HEALTHCARE EXPENDITURE IN DEVELOPING NATION.
3.2. RESTRAINT
3.2.1. HIGH MEDICATION COST.
3.2.2. STRICT GOVERNMENTAL REGULATION FOR DRUG APPROVAL.
3.3. OPPORTUNITY
3.3.1. ADOPTION OF GENETIC ENGINEERING FOR DIAGNOSIS PROCEDURE.
3.3.2. INCREASE IN R&D SPENDING BY PHARMACEUTICAL COMPANIES FOR DRUG DISCOVERY.
4. MARKET SEGMENTATION
4.1. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DRUG TYPE
4.1.1. ANTI-CLOTTING AGENTS
4.1.2. ANTIHYPERLIPIDEMIC
4.1.3. BETA BLOCKERS
4.1.4. CALCIUM CHANNEL BLOCKERS
4.1.5. DIURETICS
4.1.6. RENIN-ANGIOTENSIN SYSTEM BLOCKERS
4.1.7. OTHER
4.2. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DISEASE
4.2.1. ARRHYTHMIA
4.2.2. CORONARY ARTERY DISEASE
4.2.3. HYPERLIPIDEMIA
4.2.4. HYPERTENSION
4.2.5. PERIPHERAL ARTERY DISEASE
4.3. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DISTRIBUTION CHANNEL
4.3.1. HOSPITAL PHARMACY
4.3.2. ONLINE PHARMACY
4.3.3. RETAIL PHARMACY
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. APAC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF APAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. AMGEN
7.3. BAYER AG
7.4. BOEHRINGER INGELHEIM
7.5. BRISTOL-MYERS SQUIBB COMPANY
7.6. C. R. BARD, INC.
7.7. COOK MEDICAL
7.8. DAIICHI SANKYO CO LTD
7.9. ELI LILLY AND COMPANY
7.10. F. HOFFMANN-LA ROCHE LTD.
7.11. GILEAD SCIENCES
7.12. GLAXOSMITHKLINE
7.13. JOHNSON & JOHNSON
7.14. KPI HEALTHCARE INC
7.15. MERCK & CO. INC.
7.16. NOVARTIS AG
7.17. OTSUKA HOLDINGS CO., LTD.
7.18. PFIZER
7.19. SANOFI
7.20. TAKEDA PHARMACEUTICALS COMPANY LIMITED
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING ENVIRONMENTAL POLLUTION, EXCESSIVE ALCOHOL CONSUMPTION & SMOKING.
3.1.2. CHANGING LIFESTYLE & SHIFTS IN WORK HOURS.
3.1.3. TECHNOLOGICAL ADVANCEMENT IN HEALTHCARE.
3.1.4. INCREASING HEALTHCARE EXPENDITURE IN DEVELOPING NATION.
3.2. RESTRAINT
3.2.1. HIGH MEDICATION COST.
3.2.2. STRICT GOVERNMENTAL REGULATION FOR DRUG APPROVAL.
3.3. OPPORTUNITY
3.3.1. ADOPTION OF GENETIC ENGINEERING FOR DIAGNOSIS PROCEDURE.
3.3.2. INCREASE IN R&D SPENDING BY PHARMACEUTICAL COMPANIES FOR DRUG DISCOVERY.
4. MARKET SEGMENTATION
4.1. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DRUG TYPE
4.1.1. ANTI-CLOTTING AGENTS
4.1.2. ANTIHYPERLIPIDEMIC
4.1.3. BETA BLOCKERS
4.1.4. CALCIUM CHANNEL BLOCKERS
4.1.5. DIURETICS
4.1.6. RENIN-ANGIOTENSIN SYSTEM BLOCKERS
4.1.7. OTHER
4.2. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DISEASE
4.2.1. ARRHYTHMIA
4.2.2. CORONARY ARTERY DISEASE
4.2.3. HYPERLIPIDEMIA
4.2.4. HYPERTENSION
4.2.5. PERIPHERAL ARTERY DISEASE
4.3. GLOBAL CARDIOVASCULAR DRUGS MARKET, BY DISTRIBUTION CHANNEL
4.3.1. HOSPITAL PHARMACY
4.3.2. ONLINE PHARMACY
4.3.3. RETAIL PHARMACY
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. APAC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF APAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. AMGEN
7.3. BAYER AG
7.4. BOEHRINGER INGELHEIM
7.5. BRISTOL-MYERS SQUIBB COMPANY
7.6. C. R. BARD, INC.
7.7. COOK MEDICAL
7.8. DAIICHI SANKYO CO LTD
7.9. ELI LILLY AND COMPANY
7.10. F. HOFFMANN-LA ROCHE LTD.
7.11. GILEAD SCIENCES
7.12. GLAXOSMITHKLINE
7.13. JOHNSON & JOHNSON
7.14. KPI HEALTHCARE INC
7.15. MERCK & CO. INC.
7.16. NOVARTIS AG
7.17. OTSUKA HOLDINGS CO., LTD.
7.18. PFIZER
7.19. SANOFI
7.20. TAKEDA PHARMACEUTICALS COMPANY LIMITED
LIST OF TABLES
TABLE 1 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE 2017-2023($ MILLION).
TABLE 2 GLOBAL ANTI-CLOTTING AGENTS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 3 GLOBAL ANTIHYPERLIPIDEMIC MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 4 GLOBAL BETA BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 5 GLOBAL CALCIUM CHANNEL BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 6 GLOBAL DIURETICS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 7 GLOBAL RENIN-ANGIOTENSIN SYSTEM BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 8 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 9 GLOBAL ARRHYTHMIA MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 10 GLOBAL CORONARY ARTERY DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 11 GLOBAL HYPERLIPIDEMIA MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 12 GLOBAL HYPERTENSION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 13 GLOBAL PERIPHERAL ARTERY DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 14 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 15 GLOBAL HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 16 GLOBAL ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 17 GLOBAL RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 18 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 19 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
TABLE 20 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
TABLE 21 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 22 NORTH AMERICA S MART PARKING MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 23 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 24 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
TABLE 25 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
TABLE 26 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 27 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 28 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 29 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
TABLE 30 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
TABLE 31 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 32 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 33 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 34 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION)
TABLE 35 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION)
TABLE 36 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION)
TABLE 37 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION)
TABLE 1 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE 2017-2023($ MILLION).
TABLE 2 GLOBAL ANTI-CLOTTING AGENTS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 3 GLOBAL ANTIHYPERLIPIDEMIC MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 4 GLOBAL BETA BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 5 GLOBAL CALCIUM CHANNEL BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 6 GLOBAL DIURETICS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 7 GLOBAL RENIN-ANGIOTENSIN SYSTEM BLOCKERS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 8 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 9 GLOBAL ARRHYTHMIA MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 10 GLOBAL CORONARY ARTERY DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 11 GLOBAL HYPERLIPIDEMIA MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 12 GLOBAL HYPERTENSION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 13 GLOBAL PERIPHERAL ARTERY DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 14 GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 15 GLOBAL HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 16 GLOBAL ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 17 GLOBAL RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 18 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 19 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
TABLE 20 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
TABLE 21 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 22 NORTH AMERICA S MART PARKING MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 23 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 24 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
TABLE 25 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
TABLE 26 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 27 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 28 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 29 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION).
TABLE 30 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION).
TABLE 31 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION).
TABLE 32 ASIA PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION).
TABLE 33 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 34 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DEVICES 2017-2023($ MILLION)
TABLE 35 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUG TYPE2017-2023($ MILLION)
TABLE 36 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE 2017-2023($ MILLION)
TABLE 37 REST OF THE WORLD (ROW) CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, BY DISTRIBUTION CHANNEL 2017-2023($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY DRUG TYPE2017 VS 2023(IN %)
FIGURE 2 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY DISEASE TYPE 2017 VS 2023(IN %)
FIGURE 3 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY DISTRIBUTION CHANNEL 2017 VS 2023(IN %)
FIGURE 4 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 5 UNITED STATES CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 6 CANADA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 7 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 8 UK CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 9 GERMANY CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 11 FRANCE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 12 ITALY CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 13 REST OF EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 14 ASIA PACIFIC REGION CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 15 INDIA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 16 CHINA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 17 JAPAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 18 REST OF ASIA PACIFIC REGION CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 19 REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. AMGEN
3. BAYER AG
4. BOEHRINGER INGELHEIM
5. BRISTOL-MYERS SQUIBB COMPANY
6. C. R. BARD, INC.
7. COOK MEDICAL
8. DAIICHI SANKYO CO LTD
9. ELI LILLY AND COMPANY
10. F. HOFFMANN-LA ROCHE LTD.
11. GILEAD SCIENCES
12. GLAXOSMITHKLINE
13. JOHNSON & JOHNSON
14. KPI HEALTHCARE INC
15. MERCK & CO. INC.
16. NOVARTIS AG
17. OTSUKA HOLDINGS CO., LTD.
18. PFIZER
19. SANOFI
20. TAKEDA PHARMACEUTICALS COMPANY LIMITED
FIGURE 1 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY DRUG TYPE2017 VS 2023(IN %)
FIGURE 2 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY DISEASE TYPE 2017 VS 2023(IN %)
FIGURE 3 GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY DISTRIBUTION CHANNEL 2017 VS 2023(IN %)
FIGURE 4 NORTH AMERICA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 5 UNITED STATES CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 6 CANADA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 7 EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 8 UK CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 9 GERMANY CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 11 FRANCE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 12 ITALY CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 13 REST OF EUROPE CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 14 ASIA PACIFIC REGION CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 15 INDIA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 16 CHINA CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 17 JAPAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 18 REST OF ASIA PACIFIC REGION CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 19 REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. AMGEN
3. BAYER AG
4. BOEHRINGER INGELHEIM
5. BRISTOL-MYERS SQUIBB COMPANY
6. C. R. BARD, INC.
7. COOK MEDICAL
8. DAIICHI SANKYO CO LTD
9. ELI LILLY AND COMPANY
10. F. HOFFMANN-LA ROCHE LTD.
11. GILEAD SCIENCES
12. GLAXOSMITHKLINE
13. JOHNSON & JOHNSON
14. KPI HEALTHCARE INC
15. MERCK & CO. INC.
16. NOVARTIS AG
17. OTSUKA HOLDINGS CO., LTD.
18. PFIZER
19. SANOFI
20. TAKEDA PHARMACEUTICALS COMPANY LIMITED
